Biotechnology News

Astellas partners with Sangamo on cutting-edge gene therapy

Astellas Pharma has struck a licensing agreement with Sangamo Therapeutics to make use of its neurotropic adeno-associated virus capsid, STAC-BBB. 20 December 2024

Fibrotic diseases company Certa acquires OccuRx

Privately-held Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx. 19 December 2024

Merck & Co cuts TIGIT and LAG-3 programs

US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. 18 December 2024

More Biotechnology News >

Exclusive

Relation's $45 million upfront GSK collaboration all part of right technology, right biology, right time

Pfizer's rollercoaster ride and what comes next

Toward a functional cure: J&J's ambitions in multiple myeloma

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.

In Brief

BRIEF—Mexican approval for Alzheimer’s drug Leqembi

The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024

More Biotechnology News In Brief >

Biotechnology

BRIEF—Eisai launches Alzheimer’s drug Leqembi in South Korea

28 November 2024

Pharmaceutical

BRIEF—Centauri given $1.25m to advance antimicrobials

25 November 2024

Biotechnology

BRIEF—Halozyme withdraws non-binding offer for Evotec

23 November 2024

Biotechnology

argenX spinoff secures series A extension to fight blood cancer

22 November 2024

Pharmaceutical

BRIEF—Brookfield mulls $7.4 billion bid for Grifols

19 November 2024

Biotechnology

BRIEF—Eisai updates Leqembi outlook

11 November 2024

Mergers and Acquisitions

Shionogi to acquire full ownership of joint ventures with Ping An

Japanese drugmaker Shionogi has announced that it will acquire full ownership of its joint ventures with subsidiaries of Ping An Insurance. 23 December 2024

Fibrotic diseases company Certa acquires OccuRx

19 December 2024

Cara calls it a day, teams up with Tvardi on antifibrotics

18 December 2024

Abliva acquisition ups rare disease focus for Pharming

16 December 2024

AbbVie nabs autoimmune diseases specialist Nimble

13 December 2024

Major overhaul at BenevolentAI includes possible delisting

12 December 2024

Atlas pledges “disciplined approach” for new $450 million biotech fund

6 December 2024

More Biotechnology News M&A >

Editor's Pick

Pfizer’s DMD candidate misses Phase III goals

13 June 2024

FDA slaps clinical hold on MediLink/BioNTech’s ADC drug trial

17 June 2024

EC approves Sobi’s Altuvoct for hemophilia A

19 June 2024

Boardroom

Ottimo Pharma raises over $140 million

Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024

Igyxos Biotherapeutics strengthens leadership team

French biotech Igyxos Biotherapeutics today announced the appointments of Florent Ferré as chief executive and Dr Elke Bestel as chief medical officer to reinforce its management team and executive committee. 19 December 2024

Richard Sachse joins Anaveon as CMO

Swiss immune-oncology specialist Anaveon has appointed Richard Sachse as its chief medical officer (CMO) effective February 1, 2025. 18 December 2024

New CEO to advance VectorY’s ALS therapy VTx-002

VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024

More Biotechnology News In The Boardrom >

Biotechnology News

Exclusive

Company Spotlight

Most Read

In Brief

Mergers and Acquisitions

Editor's Pick

Boardroom